Log in

PDEX PRO DEX INC NASDAQ · United States

PRO DEX INC (PDEX) news

PRO DEX INC is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PDEX, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest PRO DEX INC news

We have not published a story on PRO DEX INC yet. When there is news, it will appear here.

What PRO DEX INC does

Pro-Dex designs, develops and manufactures autoclavable, battery-powered and electric multi-function surgical drivers and shavers used primarily in orthopedic, thoracic and craniomaxillofacial surgery. It holds patented adaptive torque-limiting technology and proprietary sealing solutions, and sells mainly to medical device distributors and original equipment manufacturers. It also provides engineering, quality and regulatory consulting services and makes rotary air motors, a de minimis part of the business. In February 2026 it acquired Advanced Precision Machining, LLC, a Costa Mesa manufacturer that makes machined sub-assemblies for Pro-Dex and parts and assemblies for the aerospace and defense industries. Medical device products are developed under exclusive development and supply agreements, machined in Irvine, California and assembled in Tustin, California. Medical devices were 80% of fiscal 2026 total sales of 77,548 thousand dollars.

Product or programWhat it isStage
Surgical drivers and shaversAutoclavable, battery-powered and electric multi-function surgical drivers used in orthopedic, thoracic and craniomaxillsold, mainly to medical device distributors and original equipment manufacturers
Rotary air motorsMotors sold to a range of industries, a de minimis part of the businesssold
Precision machined parts and assembliesParts for aerospace and defense industries through Advanced Precision Machining, LLCselling since fiscal 2026

Summarised from the company's 10-K filed Sep 3, 2026.

PRO DEX INC annual financials

LineFY ended Jun 30, 2026FY ended Jun 30, 2025
Revenue$77.5 million$66.6 million
Research and development$3.3 million$3.6 million
Net income (loss)$13.7 million$9.0 million
Cash from operations$7.2 million-$1.7 million
Cash and equivalents$8.2 million$419,000
Short-term investments$1.1 million$6.7 million

Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $11.8 million, plus short-term investments of $1.2 million, $13.0 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about PRO DEX INC

What is the ticker symbol of PRO DEX INC?

PRO DEX INC trades under the ticker PDEX on NASDAQ.

Where is PRO DEX INC listed?

PRO DEX INC is listed on NASDAQ.

Which country or territory is PRO DEX INC listed under?

Our directory records PRO DEX INC under United States.

Does aibio.space cover PRO DEX INC?

aibio.space lists PRO DEX INC among 2,820 public biotech companies and publishes its news here as stories appear.

What does PRO DEX INC develop?

Pro-Dex designs, develops and manufactures autoclavable, battery-powered and electric multi-function surgical drivers and shavers used primarily in orthopedic, thoracic and craniomaxillofacial surgery. It holds patented adaptive torque-limiting technology and proprietary sealing solutions, and sells mainly to medical device distributors and original equipment manufacturers.

What is Surgical drivers and shavers from PRO DEX INC?

Surgical drivers and shavers: Autoclavable, battery-powered and electric multi-function surgical drivers used in orthopedic, thoracic and craniomaxill Stage: sold, mainly to medical device distributors and original equipment manufacturers.

What is Rotary air motors from PRO DEX INC?

Rotary air motors: Motors sold to a range of industries, a de minimis part of the business Stage: sold.

What was PRO DEX INC's revenue last year?

$77.5 million for the fiscal year ended Jun 30, 2026, as reported to the SEC.

Is PRO DEX INC profitable?

PRO DEX INC reported net income of $13.7 million for the fiscal year ended Jun 30, 2026, and generated $7.2 million of cash from operations, per its annual report to the SEC.

How much does PRO DEX INC spend on research and development?

$3.3 million in the fiscal year ended Jun 30, 2026, per its annual report.

How much cash does PRO DEX INC have?

$13.0 million in cash and short-term investments at Sep 30, 2026, per its 10-Q.

Investor discussion: PRO DEX INC

Members talk about PRO DEX INC (PDEX). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:PDEX on TradingView.

Listing details

PRO DEX INC is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PDEX, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
PRO DEX INC
Ticker
PDEX
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.